SC 13G/A | 2014-02-06 | JENNISON ASSOCIATES LLC | Celldex Therapeutics, Inc. | 3,981,806 | 4.5% | EDGAR |
SC 13G/A | 2014-02-06 | JENNISON ASSOCIATES LLC | Celldex Therapeutics, Inc. | 3,981,806 | 4.5% | EDGAR |
SC 13G/A | 2014-01-28 | BlackRock Inc. | Celldex Therapeutics, Inc. | 5,891,176 | 6.7% | EDGAR |
SC 13G | 2013-09-10 | FMR LLC | Celldex Therapeutics, Inc. | 8,269,125 | 10.2% | EDGAR |
SC 13G | 2013-04-22 | SAC Capital Advisors LP | Celldex Therapeutics, Inc. | 4,000,255 | 4.9% | EDGAR |
SC 13G | 2013-04-05 | SAC Capital Advisors LP | Celldex Therapeutics, Inc. | 3,931,355 | 4.9% | EDGAR |
SC 13G | 2013-02-13 | PRUDENTIAL FINANCIAL INC | Celldex Therapeutics, Inc. | 3,659,226 | 5.9% | EDGAR |
SC 13G | 2013-02-11 | JENNISON ASSOCIATES LLC | Celldex Therapeutics, Inc. | 3,538,941 | 5.7% | EDGAR |
SC 13G | 2013-01-30 | BlackRock Inc. | Celldex Therapeutics, Inc. | 5,361,581 | 8.6% | EDGAR |
SC 13G | 2012-12-28 | Ridgeback Capital Investments L.P. | Celldex Therapeutics, Inc. | 3,804,646 | 6.1% | EDGAR |
SC 13G/A | 2012-03-12 | BlackRock Inc. | Celldex Therapeutics, Inc. | 2,736,010 | 4.8% | EDGAR |
SC 13G/A | 2012-02-13 | BlackRock Inc. | Celldex Therapeutics, Inc. | 2,761,784 | 6.3% | EDGAR |
SC 13G | 2011-05-26 | HealthCor Management, L.P. | Celldex Therapeutics, Inc. | 2,500,000 | 5.9% | EDGAR |
SC 13G | 2011-02-03 | BlackRock Inc. | Celldex Therapeutics, Inc. | 1,887,847 | 5.9% | EDGAR |
SC 13D/A | 2009-12-23 | BRISTOL MYERS SQUIBB CO | Celldex Therapeutics, Inc. | 1,487,464 | 4.7% | EDGAR |
SC 13D/A | 2009-12-15 | BRISTOL MYERS SQUIBB CO | Celldex Therapeutics, Inc. | 1,892,819 | 6.0% | EDGAR |
SC 13D/A | 2009-12-09 | BRISTOL MYERS SQUIBB CO | Celldex Therapeutics, Inc. | 2,474,947 | 7.8% | EDGAR |
SC 13D/A | 2009-11-25 | BRISTOL MYERS SQUIBB CO | Celldex Therapeutics, Inc. | 2,889,223 | 9.1% | EDGAR |
SC 13D/A | 2009-06-26 | MEDAREX INC | Celldex Therapeutics, Inc. | 2,960,848 | 18.7% | EDGAR |
SC 13G | 2009-05-27 | APAX PARTNERS EUROPE MANAGERS LTD | Celldex Therapeutics, Inc. | 1,384,663 | 8.8% | EDGAR |